Disease · MONDO_0100081

sleep disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sleep disorder. Diseases, record MONDO_0100081. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100081

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sleep disorder; Open Targets
Open Targets ID: MONDO_0100081; Open Targets
Other names: Sleep Disorders, disturbances, sleep, parasomnia, sleep disturbance, sleep disturbances; Open Targets
NCI Thesaurus: C3376; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 28 drugs, from DailyMed; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ARMODAFINIL	CHEMBL1201192	Small molecule	Approval	DailyMed	9	2	2	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 3	ClinicalTrials.gov	11	11	10	Drugs and targets
ZOLPIDEM	CHEMBL911	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRAZODONE	CHEMBL621	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MIRTAZAPINE	CHEMBL654	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ZOPICLONE	CHEMBL135400	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
SUVOREXANT	CHEMBL1083659	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DIPHENHYDRAMINE	CHEMBL657	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets73

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR2A	5-hydroxytryptamine receptor 2A	3	Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
GABRA1	GABA A receptor alpha-1/beta-1/gamma-2	2	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; agonist GABA site positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRB1	GABA A receptor alpha-1/beta-1/gamma-2	2	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; agonist GABA site positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
HCRTR1	Orexin receptor	2	Orexin receptor antagonist	Phase 2	https://conductscience.org/library/genes/3061	Drugs and targets
HCRTR2	Orexin receptor	2	Orexin receptor antagonist	Phase 2	https://conductscience.org/library/genes/3062	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	2	Serotonin 2c (5-HT2c) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets

1 to 10 of 73

See all 73 targets

Trials32

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00830115	Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders		1,045	2010-09-15	Sleep Disorders, Non-Erosive Reflux Disease, Gastroesophageal Reflux Disease	PANTOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00228553	Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness	Phase 3	743	2010-03-31	Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder	ARMODAFINIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00080288	Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD	Phase 3	254	2009-09-23	Excessive Sleepiness, Shift Work Sleep Disorder	ARMODAFINIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT03789214	Medical Management of Sleep Disturbance During Opioid Tapering	Phase 2	90	2022-08-08	Opioid Dependence, Opioid Withdrawal, Sleep Disturbance	SUVOREXANT	Its record names the disease	ClinicalTrials.gov
NCT02386319	Anxiolytic and Analgesic Effects of Melatonin	Phase 3	36	2021-09-02	Anxiety	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT00238108	Melatonin Supplements for Improving Sleep in Individuals With Hypertension	Phase 2	16	2012-09-25	Sleep Disorders, Hypertension	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT00965575	Pilot Study of Melatonin and Epilepsy	Phase 2	11	2020-10-01	Epilepsy	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT04204798	Dexmedetomidine and Outcomes of Elderly Admitted to ICU After Surgery	Not applicable	1,410		Elderly, Surgery, Intensive Care Unit, Dexmedetomidine, Overall Survival	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov
NCT06404112	RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)	Phase 2	469		Long COVID, Long COVID-19, Sleep Disturbance	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT00313885	Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia	Phase 2	205		Fibromyalgia, Sleep, Chronic Pain	EPLIVANSERIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 32

See all 32 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Armodafinil 150 mg/Day vs Placebo: serious adverse events	1 of 123	1 of 122	245	NCT00080288	Trial comparisons
Armodafinil 150 mg/Day vs Placebo: Clinical Global Impression of Change (CGI-C)	112 of 112	104 of 104	216	NCT00080288	Trial comparisons
Melatonin vs Placebo: deaths from any cause	0 of 16	0 of 17	33	NCT02386319	Trial comparisons
Melatonin vs Placebo: serious adverse events	0 of 16	0 of 17	33	NCT02386319	Trial comparisons
Melatonin vs Placebo: serious adverse events	0 of 10	0 of 10	20	NCT00965575	Trial comparisons
Melatonin vs Placebo: serious adverse events	0 of 8	0 of 8	16	NCT00238108	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
18972769	RESULT	1	PubMed
34635802	DERIVED	1	PubMed
33319916	DERIVED	1	PubMed
33189083	DERIVED	2	PubMed
32912180	DERIVED	1	PubMed
28609128	DERIVED	1	PubMed
24495406	DERIVED	1	PubMed
23024438	DERIVED	1	PubMed
19880686	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100081

GET https://conductscience.org/api/diseases/v1/MONDO_0100081/drugs?page=2

API reference For AI assistants